XpressBio
Private Company
Funding information not available
Overview
XpressBio operates as a reagent and contract service provider in the life sciences tools sector, focusing on antibodies and diagnostics. Its business model is built on supplying essential research components and assay development services, positioning it as a support entity for broader biomedical innovation rather than a drug developer. As a privately held company, it likely generates steady revenue from its product sales and service contracts, catering to a stable but competitive market. Its long operational history since 2005 suggests an established customer base and operational maturity.
Technology Platform
Integrated biological reagent production and assay development service platform, specializing in custom antibody generation, protein expression/purification, and immunoassay development.
Opportunities
Risk Factors
Competitive Landscape
XpressBio competes in the fragmented life sciences reagents and services market against giants like Thermo Fisher Scientific, Abcam, and Merck, as well as numerous small-to-midsize specialty providers. Its differentiation hinges on personalized service, custom capabilities, and niche expertise, rather than scale or breadth of catalog.